DNA Repair Mechanisms

Introduction

Introduction to DNA Repair Mechanisms

DNA repair mechanisms are essential cellular processes that maintain genomic integrity by correcting damage caused by endogenous and exogenous agents. Errors in DNA replication, exposure to ultraviolet (UV) radiation, chemical mutagens, and reactive oxygen species can introduce lesions such as base modifications, single-strand breaks, or double-strand breaks. Without efficient repair, these lesions can lead to mutations, genomic instability, and diseases such as cancer. Understanding these mechanisms is fundamental to biochemistry and molecular medicine.

Importance in Clinical Medicine

Defects in DNA repair pathways are associated with a spectrum of inherited disorders, increased cancer susceptibility, and therapeutic resistance in oncology. For example, mutations in genes involved in nucleotide excision repair (NER) cause xeroderma pigmentosum, a condition characterized by extreme UV sensitivity and skin cancer risk. Similarly, defects in homologous recombination (HR) or mismatch repair (MMR) are linked to hereditary breast and ovarian cancer syndromes and Lynch syndrome, respectively.

Study

Base Excision Repair (BER)

Base excision repair is the primary pathway for correcting small, non-helix-distorting base lesions such as those caused by oxidation, alkylation, or deamination. The process begins with a DNA glycosylase that recognizes and removes the damaged base, creating an apurinic/apyrimidinic (AP) site. AP endonuclease then cleaves the DNA backbone, and DNA polymerase β fills the gap, followed by ligation via DNA ligase III. BER is critical for preventing mutations from oxidative damage, which is a common byproduct of cellular metabolism.

Nucleotide Excision Repair (NER)

NER repairs bulky, helix-distorting lesions such as pyrimidine dimers induced by UV radiation. The pathway involves two sub-pathways: global genome NER (GG-NER) and transcription-coupled NER (TC-NER). In GG-NER, the XPC-RAD23B complex recognizes the lesion, while TC-NER is triggered by stalled RNA polymerase during transcription. After recognition, the DNA around the lesion is unwound by TFIIH, and a 24–32 nucleotide segment is excised by endonucleases XPF-ERCC1 and XPG. The gap is then filled by DNA polymerase δ or ε and sealed by DNA ligase I.

Mismatch Repair (MMR)

Mismatch repair corrects errors that escape proofreading during DNA replication, such as base-base mismatches and insertion-deletion loops. In humans, the MutSα (MSH2-MSH6) or MutSβ (MSH2-MSH3) complex recognizes the mismatch, while MutLα (MLH1-PMS2) coordinates the excision process. The newly synthesized strand is identified by nicks, and exonuclease 1 degrades the error-containing segment. DNA polymerase δ resynthesizes the strand, and DNA ligase I completes the repair. Defects in MMR lead to microsatellite instability, a hallmark of Lynch syndrome.

Double-Strand Break Repair: Homologous Recombination and Non-Homologous End Joining

Double-strand breaks (DSBs) are among the most cytotoxic DNA lesions and are repaired by two major pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). HR is error-free and occurs during the S and G2 phases of the cell cycle, using the sister chromatid as a template. Key proteins include BRCA1, BRCA2, and RAD51. In contrast, NHEJ is active throughout the cell cycle and directly ligates broken DNA ends, often resulting in small insertions or deletions. While NHEJ is efficient, it is error-prone and can contribute to chromosomal translocations.

DNA Damage Response and Clinical Implications

The DNA damage response (DDR) is a coordinated signaling network that detects DNA damage and activates cell cycle checkpoints, DNA repair, or apoptosis. Key regulators include ATM, ATR, and p53. Mutations in DDR genes, such as ATM or TP53, predispose individuals to cancer and neurodegenerative diseases. Additionally, DDR pathways are exploited in cancer therapy; for example, PARP inhibitors are used to treat BRCA-mutated cancers by inducing synthetic lethality through inhibition of single-strand break repair.

Summary

Key Takeaways

DNA repair mechanisms are vital for maintaining genomic stability and preventing disease. The major pathways—BER, NER, MMR, HR, and NHEJ—each target specific types of DNA damage. Defects in these pathways are linked to inherited syndromes, cancer predisposition, and therapeutic resistance. Understanding these processes is crucial for diagnosing genetic disorders and developing targeted cancer therapies.

Clinical Correlate

Clinically, DNA repair deficiencies are exploited in precision oncology. For instance, tumors with BRCA mutations are sensitive to PARP inhibitors due to synthetic lethality. Similarly, microsatellite instability in MMR-deficient tumors predicts response to immune checkpoint inhibitors. Genetic testing for mutations in DNA repair genes (e.g., BRCA1/2, MLH1, MSH2) is now standard in managing hereditary cancer syndromes and guiding treatment decisions.

Future Directions

Emerging research focuses on targeting DNA repair pathways to enhance chemotherapy efficacy and overcome resistance. Additionally, advances in gene editing and CRISPR-based therapies may offer new strategies to correct DNA repair defects in inherited disorders. Understanding the interplay between DNA repair and immune surveillance is also critical for developing novel immunotherapies.